Breast Cancer Treatment Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 - 2022, the breast cancer treatment market was valued at USD 10,682.6 Mn in 2015, and is expected to reach USD 17,345.8 Mn by 2022, expanding at a CAGR of 7.6% from 2016 to 2022.
Browse Full Report Visit - http://www.acutemarketreports.com/report/breast-cancer-treatment-market
Market Insights:
Breast cancer is typically detected either during a screening examination, before symptoms have developed, or after a woman notices a lump. According to market experts, breast cancer is the second-largest cause of cancer deaths globally. The rising prevalence of breast cancer across the developed nations has boosted the involvement of non-governmental associations that are spreading awareness related to breast cancer diagnostics and treatment in public. Therapeutic treatment preferred to treat breast cancer involves synthetic to biological drugs. The awareness created around the world in last decade has assisted the market growth along with market introduction of premium priced therapies. Moreover, drugs for breast cancer have seen accelerated approvals, thereby providing impetus for breast cancer research and shifting the equilibrium toward research of new effective pathways for intervention of breast cancer. On the other hand, the geographical analysis of breast cancer treatment market projected North America and Europe as the dominant regions followed by Asia-Pacific. The key factors driving the breast cancer market in the world include developed research and development facilities, upcoming drug launches, and mounting incidences and awareness of the breast cancer in developing countries. Thus, rising incidences of breast cancer and novel product approvals will lead to significant market growth during the forecast period, despite generic sales erosion resulting from patent expirations.
Breast cancer is typically detected either during a screening examination, before symptoms have developed, or after a woman notices a lump. According to market experts, breast cancer is the second-largest cause of cancer deaths globally. The rising prevalence of breast cancer across the developed nations has boosted the involvement of non-governmental associations that are spreading awareness related to breast cancer diagnostics and treatment in public. Therapeutic treatment preferred to treat breast cancer involves synthetic to biological drugs. The awareness created around the world in last decade has assisted the market growth along with market introduction of premium priced therapies. Moreover, drugs for breast cancer have seen accelerated approvals, thereby providing impetus for breast cancer research and shifting the equilibrium toward research of new effective pathways for intervention of breast cancer. On the other hand, the geographical analysis of breast cancer treatment market projected North America and Europe as the dominant regions followed by Asia-Pacific. The key factors driving the breast cancer market in the world include developed research and development facilities, upcoming drug launches, and mounting incidences and awareness of the breast cancer in developing countries. Thus, rising incidences of breast cancer and novel product approvals will lead to significant market growth during the forecast period, despite generic sales erosion resulting from patent expirations.
Pipeline Analysis:
The phase III drugs included in the pipeline analysis are Abemaciclib (Eli Lily & Company), Buparlisib (Novartis), NeuVax (Galena Biopharma), Niraparib (Tesaro), Lynparza (AstraZeneca), Veliparib (AbbVie), Neratinib (Puma Biotechnology), Ribociclib (Novartis) and others. According to market experts, these upcoming drugs assure to provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the currently available breast cancer treatment. Thus, future commercialization of these molecules during the forecast period 2016 – 2022 is anticipated to have a reflective impact on the growth of the overall breast cancer treatment market.
The phase III drugs included in the pipeline analysis are Abemaciclib (Eli Lily & Company), Buparlisib (Novartis), NeuVax (Galena Biopharma), Niraparib (Tesaro), Lynparza (AstraZeneca), Veliparib (AbbVie), Neratinib (Puma Biotechnology), Ribociclib (Novartis) and others. According to market experts, these upcoming drugs assure to provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the currently available breast cancer treatment. Thus, future commercialization of these molecules during the forecast period 2016 – 2022 is anticipated to have a reflective impact on the growth of the overall breast cancer treatment market.
Key Market Movements:
• North America presently dominates the overall market and is also projected to experience the fastest growth throughout the forecast period
• The recent market entry of novel drugs including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent have boosted the overall growth of breast cancer treatment market
• The companies have been able to develop efficient and commercially successful products by studying pathophysiology of breast cancer in detail, e.g. Herceptin, which is build on the existing scientific groundwork.
• North America presently dominates the overall market and is also projected to experience the fastest growth throughout the forecast period
• The recent market entry of novel drugs including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent have boosted the overall growth of breast cancer treatment market
• The companies have been able to develop efficient and commercially successful products by studying pathophysiology of breast cancer in detail, e.g. Herceptin, which is build on the existing scientific groundwork.
Browse All Reports of This Category - http://www.acutemarketreports.com/category/pharmaceutical-market
Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
Chapter 2 Executive Summary
2.1 Global Breast Cancer Treatment Market Portaiture
2.2 Global Breast Cancer Treatment Market Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Breast Cancer Treatment Market, by Geography, 2015 & 2022 (USD Mn)
2.1 Global Breast Cancer Treatment Market Portaiture
2.2 Global Breast Cancer Treatment Market Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Breast Cancer Treatment Market, by Geography, 2015 & 2022 (USD Mn)
Chapter 3 Breast Cancer Treatment : Market Dynamics and Outlook
3.1 Breast Cancer Treatment Market Overview
3.2 Breast Cancer Disease Overview and Treatments
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Breast Cancer Treatment Market, 2015 (Value %)
3.1 Breast Cancer Treatment Market Overview
3.2 Breast Cancer Disease Overview and Treatments
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Breast Cancer Treatment Market, 2015 (Value %)
Chapter 4 Global Breast Cancer Treatment Market, By Type of Drug Class
4.1 Preface
4.2 HER2 Inhibitors
4.2.1 Trastuzumab
4.2.2 Pertuzumab
4.2.3 Ado-trastuzumab emtansine
4.2.4 Lapatinib
4.3 Mitotic Inhibitors
4.3.1 Eribulin
4.3.2 Docetaxel
4.3.3 Ixabepilone
4.4 Anti-metabolites
4.4.1 Gemcitabine
4.5 Aromatase Inhibitors
4.5.1 Leterozole
4.5.2 Exemestane
4.5.3 Anastrozole
4.5.4 Palbociclib
4.5.5 Everolimus
4.6 Hormone Receptor Antagonists
4.6.1 Goserelin Acetate
4.6.2 Fulvestrant
4.6.3 Toremifene
4.7 Pipeline Analysis
4.7.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.7.1.1 Abemaciclib
4.7.1.2 Buparlisib
4.7.1.3 NeuVax
4.7.1.4 Niraparib
4.7.1.5 Lynparza
4.7.1.6 Veliparib
4.7.1.7 Neratinib
4.7.1.8 Ribociclib
4.7.1.9 Others
4.7.2 Tabular Representation of Phase II and I Drugs
4.1 Preface
4.2 HER2 Inhibitors
4.2.1 Trastuzumab
4.2.2 Pertuzumab
4.2.3 Ado-trastuzumab emtansine
4.2.4 Lapatinib
4.3 Mitotic Inhibitors
4.3.1 Eribulin
4.3.2 Docetaxel
4.3.3 Ixabepilone
4.4 Anti-metabolites
4.4.1 Gemcitabine
4.5 Aromatase Inhibitors
4.5.1 Leterozole
4.5.2 Exemestane
4.5.3 Anastrozole
4.5.4 Palbociclib
4.5.5 Everolimus
4.6 Hormone Receptor Antagonists
4.6.1 Goserelin Acetate
4.6.2 Fulvestrant
4.6.3 Toremifene
4.7 Pipeline Analysis
4.7.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.7.1.1 Abemaciclib
4.7.1.2 Buparlisib
4.7.1.3 NeuVax
4.7.1.4 Niraparib
4.7.1.5 Lynparza
4.7.1.6 Veliparib
4.7.1.7 Neratinib
4.7.1.8 Ribociclib
4.7.1.9 Others
4.7.2 Tabular Representation of Phase II and I Drugs
Chapter 5 Global Breast Cancer Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia-Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Rest of Latin America
5.6 Middle East and Africa
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia-Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Rest of Latin America
5.6 Middle East and Africa
To Get Complete Report @ http://www.acutemarketreports.com/report/breast-cancer-treatment-market
Chapter 6 Company Profiles
6.1 AstraZeneca plc
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Eisai Co., Ltd.
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Eli Lilly and Company
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.1 AstraZeneca plc
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Eisai Co., Ltd.
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Eli Lilly and Company
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
Latest Reports :
http://www.acutemarketreports.com/report/3d-bioprinters-market
http://www.acutemarketreports.com/report/3d-bioprinters-market
About - Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Contact Us :
Name : Chris Paul
ACUTE MARKET REPORTS
Designation : Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com
Our Blog :- http://www.pdfdevices.com/
